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Abstract
Background:
18F-fluorodeoxyglucose positron emission tomography (
18F-FDG-PET) is widely used in diagnostic
cancer imaging. However, the use of
18F-FDG in PET-based imaging is limited by its specificity and sensitivity. In
contrast, anti-TAG (tumor associated glycoprotein)-72 monoclonal antibodies are highly specific for binding to a
variety of adenocarcinomas, including colorectal cancer. The aim of this preliminary study was to evaluate a
complimentary determining region (CDR)-grafted humanized CH2-domain-deleted anti-TAG-72 monoclonal
antibody (HuCC49deltaCH2), radiolabeled with iodine-124 (
124I), as an antigen-directed and cancer-specific targeting
agent for PET-based imaging.
Methods: HuCC49deltaCH2 was radiolabeled with
124I. Subcutaneous tumor implants of LS174T colon
adenocarcinoma cells, which express TAG-72 antigen, were grown on athymic Nu/Nu nude mice as the xenograft
model. Intravascular (i.v.) and intraperitoneal (i.p.) administration of
124I-HuCC49deltaCH2 was then evaluated in this
xenograft mouse model at various time points from approximately 1 hour to 24 hours after injection using
microPET imaging. This was compared to i.v. injection of
18F-FDG in the same xenograft mouse model using
microPET imaging at 50 minutes after injection.
Results: At approximately 1 hour after i.v. injection,
124I-HuCC49deltaCH2 was distributed within the systemic
circulation, while at approximately 1 hour after i.p. injection,
124I-HuCC49deltaCH2 was distributed within the
peritoneal cavity. At time points from 18 hours to 24 hours after i.v. and i.p. injection,
124I-HuCC49deltaCH2
demonstrated a significantly increased level of specific localization to LS174T tumor implants (p = 0.001) when
compared to the 1 hour images. In contrast, approximately 50 minutes after i.v. injection,
18F-FDG failed to
demonstrate any increased level of specific localization to a LS174T tumor implant, but showed the propensity
toward more nonspecific uptake within the heart, Harderian glands of the bony orbits of the eyes, brown fat of
the posterior neck, kidneys, and bladder.
Conclusions: On microPET imaging,
124I-HuCC49deltaCH2 demonstrates an increased level of specific localization
to tumor implants of LS174T colon adenocarcinoma cells in the xenograft mouse model on delayed imaging,
while
18F-FDG failed to demonstrate this. The antigen-directed and cancer-specific
124I-radiolabled anti-TAG-72
monoclonal antibody conjugate,
124I-HuCC49deltaCH2, holds future potential for use in human clinical trials for
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Background
The origin of positron imaging dates back to the early
1950’s [1], culminating in the development of positron
emission tomography (PET) and its subsequent evolu-
tion over the last 40 years [1-4]. The clinical application
of PET-based imaging strategies to the field of oncology
has had a significant impact upon the care of cancer
patients [5-11]. Therefore, the development and selec-
tion of the most appropriate and specific radiotracer for
PET-based imaging is critical to its success in oncology
[12-15].
18F-fluorodeoxyglucose (
18F-FDG) is currently the
most widely used radiotracer for PET-based imaging
strategies [16]. In this regard,
18F-FDG-PET-based ima-
ging is considered state-of-the-art for the diagnostic
imaging, staging, and follow-up of a wide variety of
malignancies, including colorectal cancer [10,11]. How-
ever, there are several intrinsic limitations related to the
use of
18F-FDG-PET imaging that remain a challenge
and a concern to those involved in the care of cancer
patients [6-9,16-24]. First, false positive results can
occur with
18F-FDG-PET imaging in the presence of any
pathologic conditions in which there is a high rate of
glucose metabolism, such as inflammatory or infectious
processes. Second, false negative results can occur with
18F-FDG-PET imaging secondary to poor avidity of
18F-
FDG to certain tumor types and secondary to impaired
uptake of
18F-FDG in patients with elevated blood glu-
cose levels. Third, due to system resolution limitations,
18F-FDG-PET imaging is generally limited in its ability
to detect small-volume, early-stage primary disease or to
detect microscopic disease within the lymph nodes.
Fourth,
18F-FDG-PET imaging can produce either false
positive or false negative results secondary to the normal
physiologic accumulation of
18F-FDG within certain tis-
sues with an elevated level of glucose metabolism (most
striking in the brain and heart, and to a lesser degree in
the mucosa and smooth muscle of the stomach, small
intestine and colon, as well as in liver, spleen, skeletal
muscle, thyroid, and brown fat) and secondary to the
excretion and accumulation of
18F-FDG within the urin-
ary tract (kidneys, ureters, and bladder). Overall, these
factors have a negative impact on optimizing the specifi-
city and sensitivity of
18F-FDG-PET for accurate diag-
nostic cancer imaging [6-9,16-24].
A PET-based imaging approach that specifically tar-
gets the cancer cell environment would clearly have a
significant potential advantage for improving the accu-
racy of diagnostic cancer imaging over that of the more
nonspecific nature of
18F-FDG. In that regard, tumor-
associated glycoprotein-72 (TAG-72) is a mucin-like gly-
coprotein complex that is overexpressed by many
adenocarcinomas, including colorectal, pancreatic, gas-
tric, esophageal, ovarian, endometrial, breast, prostate,
and lung [22,24-27]. Such overexpression of TAG-72 is
noted in up to approximately 90% of these various ade-
nocarcinomas [24]. In xenograft mice bearing subcuta-
neous tumor implants of the TAG-72-expressing human
colon adenocarcinoma cell line, LS174T [27-29], anti-
TAG-72 monoclonal antibodies have been shown to
accumulate up to 18-fold higher in LS174T tumor
implants than in normal tissues [25,30,31]. Over the last
25 years, our group at The Ohio State University, as
well as others, have evaluated a variety of radioiodine
labeled anti-TAG-72 monoclonal antibodies for tumor-
specific antigen targeting at the time of surgery for
known primary, recurrent, and metastatic disease, as
well as for targeting occult disease and affected lymph
nodes in colorectal cancer patients [22,24,32-59].
Most recently, we have evaluated the complimentary
determining region (CDR)-grafted humanized CH2-
domain-deleted anti-TAG-72 monoclonal antibody,
HuCC49deltaCH2 [60-63], radiolabeled with iodine-125
(
125I), for intraoperative tumor detection of colorectal
cancer in both a preclinical xenograft mouse model and
in a human clinical trial [22,24,57-59]. Collectively, our
experience with radiolabeled anti-TAG-72 monoclonal
antibodies in combination with a handheld gamma
detection probe has clearly shown that this technology
provides the surgeon with real-time intraoperative infor-
mation for more precise tumor localization and resec-
tion and has demonstrated improved long-term patient
survival after surgery [22,24].
Because of the drawbacks of using
125I as the radioio-
dine label for anti-TAG-72 monoclonal antibodies,
including the extremely long physical half-life of
125Io f
approximately 60 days (which generates handling, sto-
rage, and disposal issues within the operating room
environment and in the surgical pathology department)
and the inability of
125I to allow for diagnostic imaging
capabilities, other radionuclides have been sought for
use with anti-TAG-72 monoclonal antibodies. One such
alternative is iodine-124 (
124I) [64]. In this regard,
124Ii s
a positron emitting radionuclide that has a physical half-
life of approximately 4.2 days, for which its positron
emitting properties makes it well-suited for PET-based
imaging and for which its shorter physical half-life sim-
plifies the handling, storage, and disposal issues.
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uate
124I-HuCC49deltaCH2 as an antigen-directed and
cancer-specific targeting agent for PET-based imaging.
Methods
Tissue culture and reagents
Cell culture medium (DMEM), fetal bovine serum (FBS),
trypsin, and other tissue culture materials were pur-
chased from Invitrogen (Carlsbad, California).
The human colon adenocarcinoma cells (LS174T)
[27-29] were purchased from American Type Culture
Collection (ATCC) (Manassas, VA). LS174T cells were
cultured in DMEM (10% FBS, 1% penicillin/streptomy-
cin) at 37°C in a humidified atmosphere with 5% CO2
and with the medium changed daily. LS174T cells were
divided weekly. LS174T cells were trypsinized, collected,
and washed with PBS, and resuspended in DMEM (10%
FBS) for the subculture process. LS174T cells were
stored in DMEM (20% FBS, 10% DMSO) in liquid N2.
DOTA chelated HuCC49deltaCH2a n t i b o d yw a ss u p -
plied by Dr. Jeffrey Schlom (Laboratory of Tumor
Immunology and Biology, National Cancer Institute,
National Institutes of Health, Bethesda, MD).
Phosphate buffered
18F-FDG (200 MBq/ml) was sup-
plied by IBA Molecular (Dulles, VA).
Iodination (
124I) of HuCC49deltaCH2
Iodogen-coated Vials
Iodogen (1,3,4,6-tetrachloro-3a-6a-diphenylglycouril)
(Pierce, Rockford, IL) was dissolved in methylene chlor-
ide (1.0 mg/ml), and 1 ml was pipetted into a sterile,
pyrogen-free 10 ml vial. The vial was rotated and dried
under nitrogen to evaporate methylene chloride.
Anion Exchange Resin Filters
100- to 200-mesh AG1X8 anion exchange resin (Bio-
Rad Labs, Richmond, CA) was washed using sterile,
pyrogen free water. The anion exchange resin was asep-
tically loaded onto a 0.22 μm filter disc (1.1 to 1.5 gram
wet resin/filter unit) (Millipore Corporation, Milford,
MA). The resin was washed using the following solu-
tions in a sequence: 10 ml sterile, pyrogen-free water; 10
ml sterile 0.1 N NaOH; 10 ml pyrogen free water; 10 ml
0.1 N sodium phosphate buffer (pH 7.4); and finally by
3.3 ml 0.1 N sodium phosphate buffer with 1% HSA.
Labeling process [65,66]
0.50 ml of HuCC49deltaCH2a n t i b o d y( 1 . 5m g / m l )w a s
added to a 10 ml vial coated with 1 mg of iodogen.
Then, 0.8 ml of phosphate buffered Na
124I (150 MBq/
ml) (IBA Molecular, Dulles, VA) was added to the vial.
The reagents were allowed to react for 15 minutes. Free
124I was removed using an exchange resin filter disc.
Then, 1 ml of 5% sucrose with 0.05% Tween 20 in saline
was used to elute the labeled antibody. The purified
124I-HuCC49deltaCH2w a sp a s s e dt h r o u g ha0 . 2 2m m
Millipore filter (Millipore Corporation, Milford, MA) for
in vivo applications. Radiolabeling efficiency was moni-
tored using thin layer chromatography, which was per-
formed on silica-gel-impregnated glass fiber sheets (Pall
Corporation, East Hills, NY). 0.02 M citrate buffer (pH
5.0) was used as the mobile phase.
Xenograft mouse model with human colon
adenocarcinoma cells (LS174T)
The human colon adenocarcinoma cells, LS174T, were
trypsinized for 2 minutes, collected, and washed with
PBS under 1000 rpm × 2 minutes. The washed cells
(5×10
6 cells) were resuspended in a mixture of 50 μlo f
PBS and 50 μl of matrigel medium (Invitrogen, Carlsbad,
California) and then injected subcutaneously into the
dorsal surface (back) of female athymic Nu/Nu nude
mice (National Cancer Institute at Frederick, Frederick,
MD) that were 4 to 6 weeks of age. The resultant LS174T
tumor implants on the xenograft mice were allowed to
grow for approximately two weeks, reaching a tumor
implant volume of up to 300 mm
3.T h ex e n o g r a f tm i c e
used in this preliminary study were not pretreated with
an oral saturated solution of potassium iodide (SSKI).
124I-HuCC49deltaCH2 and
18F-FDG injections of the
xenograft mice
Two xenograft mice were successfully injected intrave-
nously (i.v.), by way of tail vein injection, with
124I-
HuCC49deltaCH2, at a dose of 0.6 MBq and 0.75 MBq,
respectively. Two additional xenograft mice were success-
fully injected intraperitoneally (i.p.) with
124I-HuCC49del-
taCH2, at a dose of 1.4 MBq and 2.5 MBq, respectively. As
a control, one xenograft mouse was successfully injected i.
v., by way of tail vein injection, with 7.4 MBq of
18F-FDG.
Pre-injection and post-injection blood glucose levels were
not monitored in the xenograft mice.
In vitro binding studies with Cy7-labeled HuCC49del-
taCH2 on LS174T cells, in vivo pharmacokinetics and
biodistribution studies with Cy7-labeled HuCC49del-
taCH2 in xenograft mice, and ex-vivo post-mortem bio-
distribution studies with Cy7-labelled HuCC49deltaCH2
on excised tumor implants and organs (i.e., spleen, kid-
ney, lung, heart, liver, stomach, and intestine) from
xenograft mice were previously performed and reported
elsewhere [67]. These studies with Cy7-labeled
HuCC49deltaCH2 were compared to results after non-
treatment, Cy7 alone, Cy7-labeled nonspecific human
IgG, Cy7-labeled murine CC49, and pretreatment with
unlabeled murine CC49 prior to administration of Cy7-
labeled HuCC49deltaCH2 [67].
MicroPET tumor imaging of the xenograft mice
Selection of microPET imaging time points was based
on historical data as well as the physical half-lives of
18F
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124I (4.2 days). For
18F-FDG, the stan-
dard accepted injection to scan time for humans and
small animals is approximately 60 ± 10 minutes [68-70].
For
124I-HuCC49deltaCH2 injected xenograft mice, an
initial 1 hour time point for baseline microPET imaging
was used, as well as a time range of delayed microPET
imaging from 18 hours to 24 hours after administration
of
124I-HuCC49deltaCH2 to allow for distribution,
uptake, and clearance. At selected time points (ranging
from approximately 1 hour to 24 hours after injection of
124I-HuCC49deltaCH2), the xenograft mice were
anesthetized with i.p. Ketamine (100 mg/kg)/Xylazine
(10 mg/kg) and then scanned on an Inveon microPET
scanner (Siemens Medical Solutions, Knoxville, TN).
Image acquisition and analysis were performed by using
Inveon Acquisition Workplace (Siemens Medical Solu-
tions, Knoxville, TN). Xenograft mice initially under-
went a transmission scan with a cobalt-57 source for
402 seconds for attenuation correction and quantifica-
tion. Xenograft mice then underwent a PET emission
scan at approximately 1 hour, 18 hours, and 20 hours
after injection of
124I-HuCC49deltaCH2 with an acquisi-
tion time of 400 seconds and again at approximately 23
hours or 24 hours after injection of
124I-HuCC49del-
taCH2 with an acquisition time of 800 seconds. For the
18F-FDG injected xenograft mouse, a PET emission scan
was obtained at approximately 50 minutes after injection
of
18F-FDG with an acquisition time of 400 seconds.
The energy window of all PET emission scans was set
to 350 keV to 650 keV, with a time resolution of 3.4 ns.
Each emission acquisition data set was attenuation cor-
rected with the attenuation transmission scan taken of
each individual mouse at each designated time point
and arranged into sinograms. The resultant sinograms
were iteratively reconstructed into three dimensional
volumes using an ordered-subset expectation maximiza-
tion (OSEM) reconstruction algorithm. The transmis-
sion acquisition yielded ana p p r o x i m a t i o no fb o d y
volume and anatomic localization, such that regions of
interest could be created to represent portions of the
mouse anatomy, specifically, whole body, the LS174T
tumor implant, and a designated background area (i.e.,
left lower quadrant of the abdomen).
The region of interest (ROI), for determination of
tumor implant volume, was drawn manually by qualita-
tive assessment to cover the entire tumor implant
volume by summation of voxels using the Inveon soft-
ware (Siemens Medical Solutions, Knoxville, TN) in a
manner similar to that previously published by Jensen et
al. [70]. In the study by Jensen et al., they compared the
accuracy of xenograft measurement by in vivo caliper
measurement versus microCT-based and microPET-
based measurement and found microCT to be the most
accurate measurement method [70]. We used a similar
method in conjunction with the transmission image to
generate the tumor implant volume. PET activity within
the volumetric ROI then yielded the resultant average
intensity counts for the tumor implant and for the
designated background area. Finally, to generate a quan-
tification measurement value for the activity of
124I-
HuCC49deltaCH2a n do f
18F-FDG that was imaged on
microPET within a given LS174T tumor implant, we
utilized the unitless value of the relative ratio of the
average intensity counts. This relative ratio of the aver-
age intensity counts was determined by dividing the
average intensity counts from the tumor implant volume
by the average intensity counts of the designated back-
ground area. We elected to generate this relative ratio of
the average intensity counts as a quantification measure-
ment value due to the fact that mouse body weights and
tumor implant weights were not recorded and microCT
was not obtained on all of the xenograft mice during
the course of the current preliminary study.
Statistical analysis
T h es o f t w a r ep r o g r a mI B MS P S S ®1 8f o rW i n d o w s ®
(SPSS, Inc., Chicago, Illinois) was used for the data ana-
lysis. One-way analysis of variance (ANOVA) was uti-
lized for the comparison of the relative ratio of average
intensity counts of the LS174T tumor implants.
Results
After chromatographic purification, 98% of
124Iw a s
bound to the chelated HuCC49deltaCH2a n t i b o d y ,a s
determined by thin layer chromatography. The radioac-
tivity of
124I-HuCC49deltaCH2 obtained was 15 MBq/ml.
Figures 1 and 2 show the xenograft mice injected i.v.
with
124I-HuCC49deltaCH2a tad o s eo f0 . 6M B qa n d
0.75 MBq, respectively. At approximately 1 hour after i.
v. injection,
124I-HuCC49deltaCH2w a sd i s t r i b u t e d
within the systemic circulation, and demonstrated no
significant localization within the LS174T tumor
implants. At the time points of 18 hours and 23 hours
after i.v. injection,
124I-HuCC49deltaCH2w a sf o u n dt o
have specific localization within the LS174T tumor
implants. The thyroid showed expected uptake of
124I,
secondary to the lack of pre-treatment with SSKI. The
bladder exhibited accumulation of
124I, indicating the
degradation of
124I-HuCC49deltaCH2a n dt h ee x c r e t i o n
of free
124I into the urine.
Figures 3 and 4 show the xenograft mice injected i.p.
with
124I-HuCC49deltaCH2a tad o s eo f1 . 4M B qa n d
2.5 MBq, respectively. At approximately 1 hour after i.p.
injection,
124I-HuCC49deltaCH2w a sd i s t r i b u t e do n l y
within the peritoneal cavity, and demonstrated no signif-
icant localization within the LS174T tumor implants. At
the time points of 20 hours and 24 hours after i.p. injec-
tion,
124I-HuCC49deltaCH2 was found to have specific
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thyroid showed expected uptake of
124I, secondary to
the lack of pre-treatment with SSKI. The bladder exhib-
ited accumulation of
124I, indicating the degradation of
124I-HuCC49deltaCH2 and the excretion of free
124I into
the urine.
124I-HuCC49deltaCH2 was also observed to
accumulate within the liver on the microPET images
and was most pronounced at the time points of 20
hours and 24 hours after i.p. injection of
124I-HuCC49-
deltaCH2 at a dose of 2.5 MBq (Figure 4). This was pre-
sumed to be secondary to use of the chelated form of
the HuCC49deltaCH2 antibody.
Figure 5 shows the xenograft mouse injected i.v. with
7.4 MBq of
18F-FDG and imaged by the microPET at
approximately 50 minutes after injection. Multiple sites
of tumor-nonspecific
18F-FDG accumulation were noted
in the xenograft mouse.
18F-FDG was noted to avidly
accumulate in the heart, the brown fat of the posterior
neck, and the Harderian glands within the bony orbits
of the eyes, all secondary to the high rate glucose meta-
bolism within these tissues.
18F-FDG was noted to be
rapidly eliminated from kidneys and bladder within 50
minutes after the i.v. injection. Only very minimal locali-
zation of
18F-FDG to the LS174T tumor implant was
noted in the xenograft mouse model.
To generate a quantification measurement value for
t h ea c t i v i t yo f
124I-HuCC49deltaCH2a n do f
18F-FDG
t h a tw a si m a g e do nm i c r o P E Tw i t h i nag i v e nL S 1 7 4 T
tumor implant, we utilized the unitless value of the rela-
tive ratio of the average intensity counts, as determined
by dividing the average intensity counts of the LS174T
tumor implant by the average intensity counts of the
designated background area. For comparing the localiza-
tion of
124I-HuCC49deltaCH2 within the LS174T tumor
implants at approximately 1 hour after i.v. and i.p. injec-
tion versus at 18 hours to 24 hours after i.v. and i.p.
injection, the mean relative ratio of the average intensity
counts was determined to be 0.34 (SD ± 0.29, range
Figure 1 Intravenous (i.v.) administration through the tail vein of 0.6 MBq of
124I-HuCC49deltaCH2 for microPET imaging of the
LS174T xenograft mouse model. MicoPET imaging is shown at approximately 1 hour and at 23 hours after injection in coronal, sagittal, and
transaxial views. At 23 hours after i.v. injection,
124I-HuCC49deltaCH2 was found to have specifically accumulated within the LS174T tumor
implant.
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Page 5 of 130.06 to 0.64, n = 4) at approximately 1 hour after injec-
tion as compared to 2.58 (SD ± 0.99, range 1.57 to 4.57,
n = 8) at 18, 20, 23, and 24 hours after injection (p =
0.001). This finding verifies a significantly increased
level of specific localization of
124I-HuCC49deltaCH2t o
LS174T tumor implants as compared to background tis-
sues at 18 hours to 24 hours after injection. For com-
paring the localization of
124I-HuCC49deltaCH2w i t h i n
the LS174T tumor implants for the i.v. injection route
versus the i.p. injection route, the mean relative ratio of
the average intensity counts was determined to be 2.31
(SD ± 0.71, range 1.83 to 3.356, n = 4) for the i.v. injec-
tion route at 18 and 23 hours after injection as com-
pared to 2.85 (SD ± 1.26, range 1.57 to 4.57, n = 4)
for the i.p. injection route at 20 hours and 24 hours
after injection (p = 0.481), suggesting that i.v. and i.p.
administration of
124I-HuCC49deltaCH2 achieved similar
delivery efficiency. For comparing the localization of
124I-HuCC49deltaCH2 within the LS174T tumor
implants at differing doses of
124I-HuCC49deltaCH2, the
mean relative ratio of the average intensity counts was
determined to be 2.03 (SD ± 0.14, range 1.93 to 2.13, n
= 2) at the lowest dose administered (i.e., 0.6 MBq i.v.)
as compared to 3.70 (SD ± 1.23, range 2.84 to 4.57,
n = 2) at the highest dose administered (i.e., 2.5 MBq i.
p.) (p = 0.195). Finally, for comparing the localization of
124I-HuCC49deltaCH2v e r s u s
18F-FDG within the
LS174T tumor implants, the mean relative ratio of the
average intensity counts was 2.58 (SD ± 0.99, range 1.57
to 4.57, n = 8) for
124I-HuCC49deltaCH2 at 18, 20, 23,
and 24 hours after i.v. and i.p. injection as compared to
1.05 (n = 1) for
18F-FDG at approximately 50 minutes
after i.v. injection (p = 0.188). Although this demon-
strates that there was 2.46 times greater localization of
124I-HuCC49deltaCH2 within the LS174T tumor
implants as compared to
18F-FDG, this particular
p-value did not reach statistical significance, and this is
likely attributable to the statistic restraints of comparing
Figure 2 Intravenous (i.v.) administration through the tail vein of 0.75 MBq of
124I-HuCC49deltaCH2 for microPET imaging of the
LS174T xenograft mouse model. MicoPET imaging is shown at approximately 1 hour and at 23 hours after injection in coronal, sagittal, and
transaxial views. At 23 hours after i.v. injection,
124I-HuCC49deltaCH2 was found to have specifically accumulated within the LS174T tumor
implant.
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18F-FDG injected xeno-
graft mouse to that of 8 time points for 4 xenograft
mice injected with
124I-HuCC49deltaCH2.
Discussion
In the current preliminary report,
124I-HuCC49deltaCH2
demonstrated a significantly increased level of specific
localization to LS174T tumor implants as compared to
background tissues (p = 0.001) in the xenograft mouse
model at 18 hours to 24 hours after injection as com-
pared to at approximately 1 hour after injection. In con-
trast, in the same xenograft mouse model,
18F-FDG
failed to demonstrate any increased level of specific
localization to a LS174T tumor implant as compared to
background tissues at approximately 50 minutes after
injection. These findings, although based on a limited
number of xenograft mice, re-enforce the recognized
limitations of an
18F-FDG-based PET imaging strategy
as compared to an antigen-directed and cancer-specific
124I-HuCC49deltaCH2-based PET imaging strategy.
In the current preliminary report, both i.v. and i.p.
administration of
124I-HuCC49deltaCH2 resulted in spe-
cific localization on microPET imaging to the LS174T
tumor implants in the xenograft mouse model at 18 and
23 hours and at 20 and 24 hours after injection, respec-
tively, validating the use of both injection routes for use
in preclinical animal studies evaluating
124I-HuCC49del-
taCH2. Therefore, the end result of the transport of
124I-
HuCC49deltaCH2 from the peritoneal cavity to the
LS174T tumor implants after i.p. administration was
similar to the transport of
124I-HuCC49deltaCH2f r o m
the systemic circulation to LS174T tumor implants after
i.v. administration. These results with
124I-HuCC49del-
taCH2 are consistent with previous studies which have
Figure 3 Intraperitoneal (i.p.) administration of 1.4 MBq of
124I-HuCC49deltaCH2 for microPET imaging of the LS174T xenograft mouse
model. MicoPET imaging is shown at approximately 1 hour and at 24 hours after injection in coronal, sagittal, and transaxial views. At 24 hours
after i.p. injection,
124I-HuCC49deltaCH2 was found to have specifically accumulated within the LS174T tumor implant. The area of increased
activity (yellow) seen at the hind end of the mouse on the 1 hour coronal and sagittal images represents subcutaneous activity within the tail
region due to previous failed tail vein injection. This subcutaneous activity within the tail region completely disappeared by the 24-hour image.
Some nonspecific liver uptake is noted at 24 hours after i.p. administration of 1.4 MBq of
124I-HuCC49deltaCH2 secondary to use of the chelated
form of the HuCC49deltaCH2 antibody.
Zou et al. World Journal of Surgical Oncology 2010, 8:65
http://www.wjso.com/content/8/1/65
Page 7 of 13demonstrated the efficacy of i.p. administered anti-TAG-
72 monoclonal antibodies in patients with colorectal
cancer [71,72].
Overall, these preliminary results in the LS174T colon
adenocarcinoma xenograft mouse model are very
encouraging and lay the ground work for further investi-
gations into the use of this antigen-directed and cancer-
specific
124I-radiolabeled anti-TAG-72 monoclonal
antibody conjugate in human clinical trials related to pre-
operative, intraoperative, and postoperative PET-based
imaging strategies [73]. Such an approach that utilizes
PET-based imaging in conjunction with
124I-HuCC49del-
taCH2 is clinically feasible and could potentially have a
significant impact upon the current management of col-
orectal cancer, as well as upon other TAG-72 antigen-
expressing adenocarcinomas.
Despite the promising results of our current prelimin-
ary report that clearly show that the
124I-radiolabled
anti-TAG-72 monoclonal antibody conjugate,
124I-
HuCC49deltaCH2, shows high degree of specific locali-
zation to TAG-72 antigen expressing tumor implants in
the xenograft mouse model, there are several shortcom-
ings of our current experimental study design which led
to non-optimization of our reported results and that will
need to be further addressed in future experiments.
These shortcomings are the small sample size, the lack
of thyroid block by oral administration of SSKI, the use
of the chelated form of the HuCC49deltaCH2a n t i b o d y ,
and the anesthetic and time constraints at the time of
these preliminary experiments that did not allow for
obtaining fused microPET/CT imaging of all the xeno-
graft mice studied.
First, as is shown in Figures 1, 2, 3, and 4, significant
thyroid uptake was seen on microPET imaging at the
time points of 18 hours and 23 hours after i.v. injection
and at the time points of 20 hours and 24 hours after i.
Figure 4 Intraperitoneal (i.p.) administration of 2.5 MBq of
124I-HuCC49deltaCH2 for microPET imaging of the LS174T xenograft mouse
model. MicoPET imaging is shown at approximately 1 hour and at 24 hours after injection in coronal, sagittal, and transaxial views. At 24 hours
after i.p. injection,
124I-HuCC49deltaCH2 was found to have specifically accumulated within the LS174T tumor implant. Significant nonspecific liver
uptake was most pronounced at 24 hours after i.p. administration of 2.5 MBq of
124I-HuCC49deltaCH2 secondary to use of the chelated form of
the HuCC49deltaCH2 antibody.
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124I-HuCC49deltaCH2. It has long been
well-known in the nuclear medicine literature that if the
thyroid is not blocked by the oral administration of
SSKI, then resultant thyroid uptake of circulating radio-
active iodine will freely occur [74-76]. This has been
previously experimentally evaluated with radioiodine
labeled anti-TAG-72 monoclonal antibodies [77]. As
such, in the current animal experiments, the lack of
thyroid blockade resulted in significant thyroid uptake
of free
124I as the unbound
124I-HuCC49deltaCH2
w a sm e t a b o l i z e di nt h eb o d ya n db e f o r et h ef r e ec i r c u -
lating
124I was excreted into the urine. Therefore, pre-
treatment of the xenograft mice with oral administration
of SSKI to minimize thyroid uptake of free
124Iw o u l d
have resulted in more optimal microPET imaging, thus
better illustrating our take-home message of specific
localization of
124I-HuCC49deltaCH2 to LS174T tumor
implants by minimizing the degree of thyroid localiza-
tion of free
124I. This shortcoming was an oversight on
our part and will be subsequently re-addressed in future
xenograft mouse model experiments in which the xeno-
graft mice are pretreated with oral SSKI.
Second, nonspecific liver uptake of
124I-HuCC49del-
taCH2 was seen on microPET imaging. As best illustrated
in Figure 4, significant nonspecific liver uptake was most
pronounced at the time points of 20 hours and 24 hours
after i.p. administration of the higher dose (2.5 MBq) of
124I-HuCC49deltaCH2. This nonspecific liver uptake was
less intense on microPET imaging at the time points of
20 hours and 24 hours after i.p. administration of a lower
dose (1.4 MBq) of
124I-HuCC49deltaCH2 (Figure 3) and
was minimally present on microPET imaging at the time
points of 18 hours and 23 hours after i.v. administration
of either dose (0.6 MBq or 0.75 MBq) of
124I-HuCC49-
deltaCH2( F i g u r e1a n dF i g u r e2 ) .As i m i l a rp a t t e r no f
accumulation within the liver has been previously
reported for various chelated radiolabeled CC49 mono-
clonal antibodies [78], as well as for a single-chain Fv ver-
sion of the radiolabeled CC49 monoclonal antibody [79].
It has been suggested that the high accumulation of these
radiolabeled monoclonal antibody in the liver is likely
due to the metabolism of the chelated form of the anti-
body within the liver [78]. Clearance and metabolism of
IgG antibodies occurs predominantly through the reticu-
loendothelial system (RES), primarily in the liver and
spleen, which both contain Kupffer cells [78,79]. Further-
more, IgG antibodies are bound and internalized by asia-
loglycoprotein receptors in the liver cells, increasing the
retention of IgG antibodies within the liver. Therefore,
it is our contention that the nonspecific liver uptake
of
124I-HuCC49deltaCH2 seen on microPET imaging
i se x p l a i n a b l eb yo u ru s eo fc h e l a t e df o r mo ft h e
Figure 5 Intravenous (i.v.) administration through the tail vein of 7.4 MBq of
18F-FDG for microPET imaging of LS174T xenograft
mouse model. MicroPET imaging is shown at approximately 50 minutes after injection in coronal, maximum intensity projection, and transaxial
views. Only very weak
18F-FDG activity was noted within the LS174T tumor implant. In contrast, significant tumor-nonspecific
18F-FDG
accumulation was noted in the heart, Harderian glands within the bony orbits of the eyes, brown fat of the posterior neck region, kidney, and
bladder.
Zou et al. World Journal of Surgical Oncology 2010, 8:65
http://www.wjso.com/content/8/1/65
Page 9 of 13HuCC49deltaCH2 antibody. It should be noted that our
inadvertent use of the chelated form of the HuCC49del-
taCH2 antibody was not recognized until after analysis of
the microPET imaging, as is best exemplified at the time
points of 20 hours and 24 hours after i.p. administration
of 2.5 MBq of
124I-HuCC49deltaCH2. Therefore, use of
the non-chelated form of the HuCC49deltaCH2 antibody
would have potentially eliminated the nonspecific liver
uptake of
124I-HuCC49deltaCH2, thus better illustrating
our take-home message of specific localization of
124I-
HuCC49deltaCH2 to LS174T tumor implants. This
shortcoming was an oversight on our part and will be
subsequently re-addressed in future xenograft mouse
model experiments in which the non-chelated form of
the HuCC49deltaCH2a n t i b o d yi su t i l i z e d .
Third, at the time of this preliminary animal experi-
ment, due to limitations in the type of anesthetic avail-
able (i.e., only i.p. Ketamine/Xylazine was available and
inhalation isoflurane anesthesia was not available), due
to the time constraints necessary for repetitive scanning
in both a microPET and a microCT format, and due to
the limited number of xenograft mice available, fused
microPET/CT imaging was only obtained on one of the
five xenograft mice. Therefore, while all five xenograft
mice were imaged by the dedicated microPET scanner,
only one xenograft mouse (i.v. injection of
124I-
HuCC49deltaCH2a tad o s eo f0 . 6M B q )w a sa l s o
imaged with the microCT scanner at the time point of
24 hours after i.v. injection, thus allowing for recon-
struction of fused microPET/CT images. In this particu-
lar case of fused microPET/CT imaging, the microCT
images demonstrated relatively good correlation of anat-
omy with the transmission images and assisted in the
accurate determination of tumor implant volume from
the transmission scan. It is evident within the molecular
imaging literature that fused-modality PET-based ima-
ging is superior to PET alone-based imaging, both for
the PET/CT platform and for the PET/MRI platform
[73,80-83]. These fused imaging platforms can provide
both molecular/functional information and structural
information that can more accurately and more pre-
cisely localize various disease processes. It is our inten-
tion to subsequently re-address this shortcoming in
future xenograft mouse model experiments by utilizing
a fused microPET/CT imaging platform in all of the
xenograft mice.
As a last notable point of discussion, some may con-
tend that the lack of specific localization of
18F-FDG to
the LS174T tumor implant as compared to the back-
ground tissues was the specific result of the type of
anesthetic used for the Nu/Nu nude mice in the current
preliminary study (i.e., i.p. Ketamine/Xylazine instead of
inhalation isoflurane anesthesia). It has been previously
reported that C57BL/6 mice injected with
18F-FDG and
having received Ketamine/Xylazine anesthesia demon-
strate increased blood glucose levels, as well as increased
18F-FDG activity within multiple normal tissues, such as
in muscle, lung, liver, kidney, and blood, as compared to
C57BL/6 mice injected with
18F-FDG that received no
anesthesia [84,85]. It has been suggested by some
authors that these metabolic effects are mediated
through the inhibition of insulin release, and that such
effects are most prominent in mice kept fasting for only
4 hours, but are substantially attenuated by 20 hours of
fasting [84]. In our preliminary animal experiments, the
x e n o g r a f tm i c ew e r ek e p tw i t h o u tf o o df o ra p p r o x i -
mately 14 hours prior to the injection of
18F-FDG and
124I-HuCC49deltaCH2. Therefore, the previously
described metabolic effects resulting from only a short-
duration fast should have been minimized. Furthermore,
these same authors reported that Ketamine/Xylazine
anesthesia did not significantly alter
18F-FDG activity
within Lewis lung carcinoma (LLC) subcutaneous tumor
implants on C57BL/6 mice as compared to the same
scenerio with no anesthesia [84]. In contrast to Keta-
mine/Xylazine, low dose (0.5%) inhalation isoflurane
anesthesia has been reported to resulted in no signifi-
cant increase in
18F-FDG activity within normal tissues
(i.e., muscle, lung, liver, and kidney) of C57BL/6 mice as
compared to the same scenerio with no anesthesia
[84,85]. These findings indirectly suggest that the use of
low dose (0.5%) inhalation isoflurane anesthesia for the
Nu/Nu nude mice in our current preliminary study
could have potentially provided a means to eliminate
a n yn e g a t i v ei m p a c to ft h ec h o i c eo fa n e s t h e t i co nt h e
absolute level of
18F-FDG activity within the LS174T
tumor implant and the various normal tissues. Based
upon these findings, it is our plan to use inhalation iso-
flurane anesthesia in our future proposed animal studies
in order to minimize the occurence of any such issues.
Conclusions
On microPET imaging,
124I-HuCC49deltaCH2d e m o n -
strates an increased level of specific localization to
tumor implants of LS174T colon adenocarcinoma cells
as compared to background tissues in the xenograft
mouse model, while
18F-FDG failed to demonstrate
this same finding. Clearly, a PET-based imaging
approach that utilizes
124I-HuCC49deltaCH2 is feasible
and could potentially have a significant impact upon
the current management of colorectal cancer and
other TAG-72 antigen-expressing adenocarcinomas.
This antigen-directed and cancer-specific
124I-radiol-
abled anti-TAG-72 monoclonal antibody conjugate
holds future potential for use in human clinical trials
for preoperative, intraoperative, and postoperative
PET-based imaging strategies, including fused-modality
PET-based imaging platforms.
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